Stock Evaluator: Cellyan Biotechnology Co., Ltd (HKPD)
Cellyan Biotechnology Co., Ltd HKPD
$0.41
0.00
-0.07%
August 21, 2026 4:00:00 PM
EST
Volume: 120,712
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Industrials | Air Freight & Logistics |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Cellyan Biotechnology Co., Ltd, an investment holding company, engages in the over-the counter (OTC) pharmaceutical business in Hong Kong and Mainland China. The company provides OTC pharmaceutical cross-border procurement and distribution and e-commerce supply chain services. It also offers customs clearance, drugs enlisting, warehouse, and other logistics services. In addition, it provides value-added services such as labeling, extended storage, product inspection, batch processing, and logistics support, as well as sales of health supplements and non-pharmaceutical products. The company serves e-commerce platform logistics partners, merchants, and Chinese e-commerce platforms as well as pharmaceutical distributors. The company was formerly known as Hong Kong Pharma Digital Technology Holdings Limited and changed its name to Cellyan Biotechnology Co., Ltd in December 2025. Cellyan Biotechnology Co., Ltd was incorporated in 2023 and is based in Yau Tong, Hong Kong.
Financial Summary
| Share Statistics | HKPD | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $9.6 | $135.2 | 6% |
|
| Shares Out (Mil) | 23.5 | 48.5 | 33% |
|
| Institutional Ownership | 3.1% | 47.2% | 4% |
|
| Float (Mil) | 8.6 | 34.5 | 17% |
|
| Beta | na | 0.95 | na |
|
| Avg Daily Volume (000s) | 127 | 184 | 38% |
|
| Price Change (52-week) |
(59.5%) | 65.9% | 11% |
|
| Growth | HKPD | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 10.0% | na |
|
| Net Income (5yr) | na | 3.4% | na |
|
| EPS (5yr) | na | 9.9% | na |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (7.2%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | HKPD | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $13 | $574 | 10% |
|
| Net Income (TTM) (Mil) | ($1) | $11 | 38% |
|
| EPS (TTM) | ($0.048) | $0.100 | 37% |
|
| Operating Cash Flow (TTM) (Mil) | ($1) | $16 | 31% |
|
| Net Cash Flow (TTM) (Mil) | ($1) | $-0 | 41% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $70 | 10% |
|
| Enterprise Value (Q1) (Mil) | $11 | $384 | 8% |
|
| Valuation | HKPD | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.00 | 1.62 | 21% |
|
| P/E | na | 17.5 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.8 | na |
|
| Ratios | HKPD | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 10.3% | 15.3% | 9% |
|
| Net Margin | (8.5%) | 1.4% | 22% |
|
| ROA | (10.2%) | 2.3% | 25% |
|
| ROE | (15.6%) | 5.1% | 25% |
|
| Liabilities to Assets | 25.4% | 58.7% | 17% |
|
| F-Score | 3 | 5 | na |
|
Cellyan Biotechnology Co., Ltd did not pass any screens on 8/21/2026.
